Study of Inhaled ARO-RAGE in Allergen-induced Mild Asthma

Recruiting now · Phase 2 · Has a placebo group

Conditions studied: Asthma

In brief

The purpose of this study is to evaluate the impact of inhaled ARO-RAGE on the late asthmatic response (LAR) following an inhaled allergen challenge in participants with mild atopic asthma.

Key facts

Study ID: NCT07241546
Run by: Arrowhead Pharmaceuticals
People needed: 36
Starts: 2026-03-30
Expected to finish: 2028-04-01
Last updated by the study team: 2026-06-23

Who can join

Age: 18 and older, up to 65. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

Clinically stable, mild atopic asthma (FEV1 ≥70% predicted)
Established allergy confirmed by positive skin prick test at screening
Willing and able to perform lung function tests and other study-related procedures
Participants of childbearing potential must consent to use a method of highly-effective contraception in addition to a condom during the study and for at least 90 days following the end of study or last investigational product administration, whichever is later

You may not qualify if…

Concomitant diagnosis of a clinically important pulmonary disease other than asthma
Use of corticosteroids, immunosuppressives, or anti-inflammatory medications that interfere with inhaled challenges or inflammation, or chronic use of any other medication for treatment of allergic asthma
History or current medical condition contraindicating methacholine challenge
Note: Additional inclusion/exclusion criteria may apply per protocol.

Where it is running

Research Site 1 — Vancouver, British Columbia, Canada (enrolling)
Research Site 2 — Calgary, Canada (enrolling)
Research Site 3 — Edmonton, Canada (enrolling)
Research Site 5 — Hamilton, Canada (enrolling)
Research Site 4 — Saskatoon, Canada (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.